ClinicalTrials.gg
TerminatedNCT02657369Updated Oct 15, 2019Results posted

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

A Phase 2 interventional study of Lenvatinib 24 mg in Thyroid Carcinoma, Anaplastic, sponsored by Eisai Inc.. Terminated at 30 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-10-15.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Overall response rate was 3% (only 1 out of 33 participants had confirmed PR).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States — 5 open to participants now, 14 under way, none of them phase 3. Thyroid Carcinoma, Anaplastic · United States.

Enrollment
18th of 47
34 · median 26
Started
2016
with 2 others
Phase 2
29 of 50
4 open now
Registered
26th of 50
by date

Among the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, this one is the 18th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2016, is one of 29 in phase 2, and was the 26th registered.

Thyroid Carcinoma, Anaplastic

87 studies on the registry are indexed under Thyroid Carcinoma, Anaplastic; 18 are open to participants now.

Browse Thyroid Carcinoma, Anaplastic studies →

Open to participants now

5 of the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Thyroid Carcinoma, Anaplastic studies recruiting now, 13 (100%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate objective response rate ([ORR]: complete response [CR] and partial response [PR]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.

03

Conditions studied

  • Thyroid Carcinoma, Anaplastic

Keywords

  • Lenvatinib
  • Thyroid Cancer, Anaplastic
  • Lenvima
  • E7080
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have histological diagnosis consistent of Anaplastic Thyroid Cancer (ATC). Cytologic diagnosis by fine needle aspiration alone is not sufficient. Histologic diagnosis may be made by core needle , incisional biopsy, thyroidectomy, or other surgical biopsy. Fresh tumor biopsies (re-biopsy) should be obtained whenever feasible. The central pathology review may take place prior to or after the participant starts treatment with lenvatinib.

    1. Central review of pathology is required for study participation, but not required prior to enrollment or start of treatment in order to avoid delay. If the results of central pathology review are not available prior to the start of study treatment, the confirmation of diagnosis of ATC at the local laboratory is mandatory prior to scheduled start of treatment with lenvatinib.
    2. If central pathology review indicates a diagnosis other than ATC, the participant may continue treatment with lenvatinib per standard of care, at the discretion of the treating investigator. Participants deemed to have another diagnosis (not ATC) will be taken off this study and replaced for the purpose of efficacy analyses.
    3. Differentiated thyroid carcinoma (DTC) with focus loci of ATC is allowed. If a participant has pathology showing a small focus of ATC arising out of DTC and the is not fully consistent with ATC, confirmation of ATC by biopsy is required.
    4. An incidental focus of medullary thyroid cancer (MTC), DTC, and/or poorly differentiated thyroid cancer in a participant with ATC is allowed.
    5. Histological diagnosis of ATC made through surgical resection is also acceptable.
  2. Prior , adjuvant, or palliative chemotherapy for ATC is allowed.
  3. Measurable disease based on investigator's assessments meeting the following criteria:

    1. At least 1 lesion of ≥ 10 millimeters (mm) in the longest diameter for a non-lymph node or ≥ 15 mm in the short-axis diameter for a lymph node which is serially measurable according to (RECIST) 1.1 using computerized tomography (CT) or magnetic resonance imaging (MRI).
    2. Lesions that have had external beam radiotherapy or locoregional therapies such as radiofrequency ablation must show evidence of subsequent progressive disease (substantial size increase of ≥ 20%) to be deemed a target lesion.
  4. Participants with known who have completed whole brain radiotherapy, stereotactic radiosurgery, or complete surgical resection will be eligible if they have remained clinically stable, asymptomatic, and off for 1 month prior to enrollment.
  5. All previous chemotherapy or radiation therapy-related toxicities, except dry mouth, dysphagia, esophagitis, mucositis, alopecia, and irreversible late sequelae of radiation therapy, must have resolved to Grade 0 or 1 per (CTCAE v 4.03), and all wounds from prior surgery must have adequately recovered.
  6. (ECOG) performance status of 0 to 1.
  7. Blood pressure (BP) ≤ 140/90 millimeter of mercury (mmHg) at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.
  8. Adequate renal function as evidenced by calculated ≥ 30 milliliter/ minute (mL/min) according to the Cockcroft and Gault formula.
  9. Adequate bone marrow function:

    1. (ANC) ≥ 1.5 x 10\^9/liter (L) and
    2. ≥ 9.0 grams/deciliter (g/dL) (can be corrected by growth factor or transfusion) and
    3. count ≥ 100 x 10\^9/L.
  10. Adequate blood coagulation function as evidenced by an (INR) ≤ 1.5.
  11. Adequate liver function:

    1. ≤ 1.5 x (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome;
    2. Alkaline phosphatase (ALP), (ALT), and aspartate aminotransferase (AST) ≤ 3 x ULN (≤ 5 x ULN if participant has liver ). If ALP is > 3 x ULN (in the absence of liver metastases) or > 5 x ULN (in the presence of liver metastases) AND participants are also known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.
  12. Voluntary agreement to provide written and the willingness and ability to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Differentiated thyroid cancer (DTC) or MTC. However, ATC arising out of DTC is allowed, as long as the is clinically consistent with ATC i.e., rapidly progressive and/or 18F fluorodeoxyglucose (FDG)-avid.
  2. Newly diagnosed participants who are considered appropriate candidates for comprehensive multimodality treatment (involving surgery and/or external beam radiotherapy or chemo radiotherapy).
  3. Prior treatment with lenvatinib or any tyrosine kinase inhibitor (TKI) - (except for combination therapy of radiation and reduced dose of TKI given for the purpose of radiosensitization).
  4. Major surgery within 2 weeks prior to the first dose of lenvatinib.
  5. Any anti-cancer treatment within 14 days or any agent within 30 days before the first dose of study drug.
  6. Radiotherapy within 3 weeks prior to the first dose of lenvatinib.
  7. Participants having > 1 + proteinuria on urine dipstick testing will undergo 24 hour urine collection for quantitative assessment of proteinuria. Participants with urine protein ≥ 1 gram/24 hours will be ineligible.
  8. Significant cardiovascular impairment: History of (a) congestive heart failure greater than (NYHA) Class II, (b) unstable angina, (c) myocardial infarction, (d) stroke, or (e) cardiac arrhythmia associated with impairment within 6 months of the first dose of study drug.
  9. A (ECG) abnormality, including a marked Baseline prolonged /QTc interval (e.g., a repeated demonstration of a QTc interval >500 milliseconds (msec)).
  10. Active infection requiring systemic therapy.
  11. Clinically significant hemoptysis or tumor bleeding within two weeks prior to first dose of lenvatinib.
  12. Radiographic evidence of major blood vessel invasion/infiltration.
  13. Other active (except definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within past 24 months.
  14. Scheduled for major surgery during the study.
  15. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] or human chorionic gonadotropin [hCG] test with a minimum sensitivity of 25 international units/liter (IU/L) or equivalent units of ß-hCG [or hCG]). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  16. Females of who:

    1. Do not agree to use a highly effective method of (ie, total abstinence, [if it is their preferred and usual lifestyle], an intrauterine device or intrauterine system, a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) within 30 days before study entry and throughout the entire study period and for 30 days after study drug discontinuation.
    2. Are currently totally abstinent (as their preferred and usual lifestyle), and who do not agree to be totally abstinent during the study period and for 30 days after study drug discontinuation.
    3. Are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 30 days after study drug discontinuation.
    4. Are using oral hormonal contraceptives and who do not agree to add a barrier method.

    (NOTE: All females will be considered to be of childbearing potential unless they are [amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause] or have been sterilized surgically [i.e. bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).

    For sites outside of the European Union (EU), it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, i.e. double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide.

  17. Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
  18. Known intolerance to the study drug or any of the .
  19. Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Lenvatinib

    Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.

    Drug: Lenvatinib 24 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator review using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for target lesions. CR was defined as disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in the sum of the longest diameters of target lesions, taking as reference the Baseline sum diameters. Confirmation of CR or PR was performed at least 28 days following the initial achievement of the response.

    Time frame: From the date of beginning of lenvatinib administration to the date of first documentation of disease progression or death, whichever occurred first (up to Month 27)

Secondary outcomes

  1. Progression-free Survival (PFS) Rate

    Twelve-week PFS rate was the percentage of participants in the analysis population who remain alive and progression-free at 12 weeks. PFS was defined as the time from the date of beginning of lenvatinib administration to the date of first documentation of confirmed disease progression or death, whichever occurred first. The Kaplan-Meier estimated rate method was used to estimate 12-week PFS, along with the corresponding 95% confidence interval (CI). Participants who were off study due to lost to follow up, withdrew consent, or study terminated by sponsor, had new anti-cancer treatment, had no baseline/post-baseline tumor assessments, or missed 2 or more visits prior to event were censored.

    Time frame: From the date of beginning of lenvatinib administration up to the date of first documentation of confirmed disease progression or death, whichever occurred first (up to Week 12)

  2. Overall Survival (OS) Rate

    Six-month OS rate was defined as the percentage of participants in the analysis population who are alive at 6 months. OS was defined as the time from the date of beginning of lenvatinib administration until date of death from any cause. The Kaplan-Meier estimated rate method was used to estimate six-month OS, along with the corresponding 95% CI. Participants with last known alive date as study terminated by sponsor were censored.

    Time frame: From the date of beginning of lenvatinib administration up to date of death from any cause (up to Month 6)

  3. Median PFS

    PFS was defined as the time from the date of beginning of lenvatinib administration to the date of first documentation of confirmed disease progression or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. Participants who were off study due to lost to follow up, withdrew consent, or study terminated by sponsor, had new anti-cancer treatment, had no baseline/post-baseline tumor assessments, or missed 2 or more visits prior to event were censored.

    Time frame: From the date of beginning of lenvatinib administration to the date of first documentation of confirmed disease progression or death, whichever occurred first (up to Month 27)

  4. Median OS

    OS was defined as the time from the date of beginning of lenvatinib administration until date of death from any cause. Median OS was estimated using the Kaplan-Meier method. Participants with last known alive date as study terminated by sponsor were censored.

    Time frame: From the date of beginning of lenvatinib administration up to date of death from any cause (up to Month 27)

07

Results

Posted Oct 15, 2019
Limitations and caveats
The study was terminated since overall response rate was 3% (only 1 out of 33 participants had confirmed PR).

Participant flow

Participants took part in the study at 13 investigative sites in France, Italy, United Kingdom, Australia and the United States from 07 July 2016 to 26 September 2018.

Participant flow — Overall Study
MilestoneLenvatinib 24 mg
Started34
Completed0
Not completed34
Withdrew: Death27
Withdrew: Study terminated by sponsor7

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator review using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for target lesions. CR was defined as disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in the sum of the longest diameters of target lesions, taking as reference the Baseline sum diameters. Confirmation of CR or PR was performed at least 28 days following the initial achievement of the response.

Time frame:
From the date of beginning of lenvatinib administration to the date of first documentation of disease progression or death, whichever occurred first (up to Month 27)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsLenvatinib 24 mg
Objective Response Rate (ORR)3.0 (0.1 to 15.8)
SecondaryProgression-free Survival (PFS) Rate

Twelve-week PFS rate was the percentage of participants in the analysis population who remain alive and progression-free at 12 weeks. PFS was defined as the time from the date of beginning of lenvatinib administration to the date of first documentation of confirmed disease progression or death, whichever occurred first. The Kaplan-Meier estimated rate method was used to estimate 12-week PFS, along with the corresponding 95% confidence interval (CI). Participants who were off study due to lost to follow up, withdrew consent, or study terminated by sponsor, had new anti-cancer treatment, had no baseline/post-baseline tumor assessments, or missed 2 or more visits prior to event were censored.

Time frame:
From the date of beginning of lenvatinib administration up to the date of first documentation of confirmed disease progression or death, whichever occurred first (up to Week 12)
Reported as:
Number · percentage of participants
Progression-free Survival (PFS) Rate
percentage of participantsLenvatinib 24 mg
Progression-free Survival (PFS) Rate36.4 (20.6 to 52.3)
SecondaryOverall Survival (OS) Rate

Six-month OS rate was defined as the percentage of participants in the analysis population who are alive at 6 months. OS was defined as the time from the date of beginning of lenvatinib administration until date of death from any cause. The Kaplan-Meier estimated rate method was used to estimate six-month OS, along with the corresponding 95% CI. Participants with last known alive date as study terminated by sponsor were censored.

Time frame:
From the date of beginning of lenvatinib administration up to date of death from any cause (up to Month 6)
Reported as:
Number · percentage of participants
Overall Survival (OS) Rate
percentage of participantsLenvatinib 24 mg
Overall Survival (OS) Rate41.2 (24.8 to 56.9)
SecondaryMedian PFS

PFS was defined as the time from the date of beginning of lenvatinib administration to the date of first documentation of confirmed disease progression or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. Participants who were off study due to lost to follow up, withdrew consent, or study terminated by sponsor, had new anti-cancer treatment, had no baseline/post-baseline tumor assessments, or missed 2 or more visits prior to event were censored.

Time frame:
From the date of beginning of lenvatinib administration to the date of first documentation of confirmed disease progression or death, whichever occurred first (up to Month 27)
Reported as:
Median · months
Median PFS
monthsLenvatinib 24 mg
Median PFS2.6 (1.4 to 2.8)
SecondaryMedian OS

OS was defined as the time from the date of beginning of lenvatinib administration until date of death from any cause. Median OS was estimated using the Kaplan-Meier method. Participants with last known alive date as study terminated by sponsor were censored.

Time frame:
From the date of beginning of lenvatinib administration up to date of death from any cause (up to Month 27)
Reported as:
Median · months
Median OS
monthsLenvatinib 24 mg
Median OS3.2 (2.8 to 8.2)

Adverse events

Collected over From signature of informed consent form up to 28 days after last dose of study drug (up to Month 27). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib27/34 (79.4%)25/34 (73.5%)32/34 (94.1%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventLenvatinib
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/34
DyspnoeaRespiratory, thoracic and mediastinal disorders4/34
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/34
HypertensionVascular disorders2/34
AstheniaGeneral disorders2/34
PyrexiaGeneral disorders2/34
PresyncopeNervous system disorders2/34
DysphagiaGastrointestinal disorders2/34
DehydrationMetabolism and nutrition disorders2/34
HyponatraemiaMetabolism and nutrition disorders2/34
Most frequent other events
Showing 10 of 189
Most frequent other events
EventLenvatinib
HypertensionVascular disorders18/34
FatigueGeneral disorders11/34
NauseaGastrointestinal disorders11/34
StomatitisGastrointestinal disorders10/34
Decreased appetiteMetabolism and nutrition disorders10/34
Weight decreasedInvestigations9/34
HyponatraemiaMetabolism and nutrition disorders9/34
DiarrhoeaGastrointestinal disorders8/34
ProteinuriaRenal and urinary disorders8/34
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders8/34

Baseline characteristics

The full analysis set included all participants who received at least one dose of lenvatinib.

Age, Continuous
Age, Continuous(years)Lenvatinib 24 mg
Mean65.4 ± 10.09
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 24 mg
Female21
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib 24 mg
Hispanic or Latino2
Not Hispanic or Latino29
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib 24 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White27
More than one race0
Unknown or Not Reported3
08

Study locations

30 sites
  • Scottsdale, Arizona 85259, United States
  • Duarte, California 91010, United States
  • Washington, District of Columbia 20007, United States
  • Washington, District of Columbia 20010, United States
  • Jacksonville, Florida 32224, United States
  • Miami, Florida 33136, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02215, United States
  • Rochester, Minnesota 55905, United States
  • New York, New York 10065-6007, United States
  • Durham, North Carolina 27710, United States
  • Portland, Oregon 97239, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Houston, Texas 77030, United States
  • Camperdown, New South Wales 2050, Australia
  • St Leonards, New South Wales, Australia
  • Caen cedex 05, Calvados 14076, France
  • Bordeaux, Gironde 33076, France
  • Angers Cedex 9, Maine Et Loire 49933, France
  • Lyon Cedex 08, Rhone 69373, France
  • Lyon, Rhone 69008, France
  • Villejuif cedex, Val De Marne 94805, France
  • Milano, 20133, Italy
  • Milano, 20162, Italy
  • Pisa, 56124, Italy
  • Roma, 00161, Italy
  • Siena, 53100, Italy
  • Cardiff, South Glamorgan CF14 2TL, United Kingdom
  • Glasgow, Strathclyde G12 OYN, United Kingdom
  • Sutton, Surrey SM2 5PT, United Kingdom
09

References and documents

Publications

  • Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert Y, De La Fouchardiere C, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol. 2021 Jul 20;39(21):2359-2366. doi: 10.1200/JCO.20.03093. Epub 2021 May 7. PubMed 33961488 ↗
  • Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016 Dec 3;388(10061):2783-2795. doi: 10.1016/S0140-6736(16)30172-6. Epub 2016 May 27. PubMed 27240885 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Eisai IPD sharing statement: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Sep 2018, 26 months.

Results were first posted in Oct 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2016
First posted
Jan 15, 2016
StartActual
Jul 7, 2016
Primary completionActual
Sep 26, 2018
CompletionActual
Sep 26, 2018
Results first posted
Oct 15, 2019
Last update
Oct 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02657369
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 15, 2016
Start date
Jul 7, 2016
Primary completion
Sep 26, 2018
Completion
Sep 26, 2018
Results posted
Oct 15, 2019
Last update
Oct 15, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion